IL8 recombinant mAbs are fully human or humanized antibodies designed to bind and block IL-8’s interaction with CXCR1/CXCR2 receptors. These antibodies are produced through advanced biotechnological methods:
XenoMouse Technology: Mice engineered with human immunoglobulin loci (e.g., ABX-IL8) generate fully human antibodies with high specificity .
Recombinant DNA Methods: Synthetic genes encoding IL-8-binding antibodies are cloned into mammalian cell lines (e.g., CSB-RA582227A0HU) .
Key antibodies include:
Antibody Name | Source/Host | Application | Cross-Reactivity |
---|---|---|---|
ABX-IL8 | Human | Melanoma | Human |
HuMax-IL8 | Human | Solid tumors | Human |
MAB208 | Mouse | ELISA, WB | Porcine IL-8 (100%) |
CSB-RA582227A0HU | Rabbit-derived recombinant | Flow cytometry | Human |
60141-1-Ig | Mouse | WB, IHC | Human |
IL8 mAbs block IL-8’s binding to its receptors, disrupting downstream signaling pathways:
Anti-Angiogenic Effects: Inhibit endothelial cell migration and tubule formation, reducing tumor vascularization .
Anti-Metastatic Activity: Suppress matrix metalloproteinase-2 (MMP-2) expression, limiting tumor invasion .
Autophagy and CSC Suppression: Reduce LC3B (autophagy marker) and CD44 (cancer stem cell marker) in breast cancer models .
Immune Modulation: Decrease brachyury expression, reversing epithelial-to-mesenchymal transition (EMT) and enhancing immune-mediated tumor lysis .
IL8 mAbs show promise in treating IL-8-driven cancers:
ABX-IL8 significantly inhibits subcutaneous tumor growth and metastasis in nude mice by:
Anti-IL8 mAbs suppress:
Parameter | Effect | Source |
---|---|---|
Autophagy (LC3B) | ↓ Significant reduction in tumors | |
Cancer Stem Cells (CD44) | ↓ Expression in tumor tissues | |
Tumor Microenvironment | ↓ IL-8-driven oncogenic signaling |
IL8-CXCR2 axis blockade restores CD8+ T-cell function by upregulating TIM3, enhancing anti-tumor immunity .
IL8 mAbs are widely used in preclinical studies:
Neutralization Capacity:
MAB208 neutralizes IL-8-induced chemotaxis (ND₅₀: 0.08–0.4 µg/mL) in CXCR2-transfected BaF3 cells .
Antibody | Trial Phase | Target Population | Key Outcomes |
---|---|---|---|
HuMax-IL8 (BMS-986253) | Phase I | Solid tumors | Safety and pharmacokinetics assessed; no severe adverse events reported |
Immunogenicity: Fully human antibodies (e.g., ABX-IL8) reduce immune responses compared to chimeric/humanized counterparts .
Combination Therapies: Synergies with anti-angiogenic drugs (e.g., bevacizumab) or checkpoint inhibitors are under investigation .
Biomarker Identification: IL-8 expression levels and CXCR2 status may predict treatment response .
The IL8 recombinant monoclonal antibody is produced through in vitro processes using synthetic genes. The IL8 antibody genes are initially extracted from B cells isolated from immunoreactive rabbits. These genes are then amplified and cloned into appropriate phage vectors. These vectors are subsequently introduced into mammalian cell lines, facilitating the production of functional antibodies. The IL8 recombinant monoclonal antibody is then purified through affinity chromatography. Following rigorous verification, the antibody is suitable for use in ELISA and FC applications to detect the human IL8 protein.
IL-8 is a pro-inflammatory chemokine that plays a crucial role in the immune response and inflammatory processes. Its functions include the recruitment and activation of immune cells, induction of inflammation, angiogenesis, and immune cell trafficking. While IL-8 is essential for the body's defense against infections and tissue repair, dysregulation of its activity can contribute to inflammatory diseases and cancer.